Krystal Biotech, Inc. - Common Stock (KRYS)
Frequently Asked Questions About Krystal Biotech, Inc. - Common Stock (KRYS)
Has Krystal Biotech received any regulatory approvals?
As of my knowledge cutoff date in October 2023, Krystal Biotech has not yet received full regulatory approval for any of its investigational therapies but continues to advance its clinical trials towards potential approval.
How can investors stay informed about Krystal Biotech?
Investors can stay informed about Krystal Biotech by regularly checking their official website for updates, subscribing to company newsletters, and following financial news outlets that cover biotechnology and pharmaceutical sectors.
How does Krystal Biotech's gene therapy work?
Krystal Biotech's gene therapy aims to introduce corrected genetic material into the patient's skin cells, aiding in the production of necessary proteins that are deficient or absent due to genetic mutations.
How has the stock performance of Krystal Biotech been?
The stock performance of Krystal Biotech can fluctuate based on various factors including clinical trial results, regulatory news, and broader market trends. Investors often monitor these developments closely.
Is Krystal Biotech involved in any philanthropic efforts?
Krystal Biotech has demonstrated a commitment to social responsibility by engaging with patient communities and supporting initiatives aimed at raising awareness and funds for rare diseases, aligning with its mission to improve patient outcomes.
Is Krystal Biotech publicly traded?
Yes, Krystal Biotech is publicly traded on the Nasdaq under the ticker symbol KRYS. The company went public in 2018 and has since been involved in various funding rounds to support its research initiatives.
What are some partnerships that Krystal Biotech has formed?
Krystal Biotech has engaged in several collaborations with academic institutions and research organizations to enhance its research capabilities and expedite the development of its product candidates.
What challenges does Krystal Biotech face?
Like many biotech companies, Krystal Biotech faces challenges including regulatory approvals, competition in the gene therapy space, and the need for ongoing funding to support its extensive research and clinical development programs.
What clinical trials is Krystal Biotech currently conducting?
Krystal Biotech is conducting several clinical trials to evaluate the safety and efficacy of its lead product candidate, KB103, in patients with dystrophic epidermolysis bullosa, which is progressing through various phases of clinical testing.
What does Krystal Biotech, Inc. do?
Krystal Biotech, Inc. is a biotechnology company focused on developing genetic medicines for the treatment of rare diseases. The company employs its proprietary fibroblast growth factor 1 (FGF1) platform to create innovative therapies aimed primarily at dermatological conditions.
What does the future hold for Krystal Biotech?
The future for Krystal Biotech appears promising as it advances its clinical candidates through trials and seeks to obtain regulatory approvals, with the potential to bring groundbreaking therapies to patients in need.
What financial support has Krystal Biotech received?
Krystal Biotech has successfully raised capital through public offerings and private placements, allowing the company to fund its research and development efforts effectively, as well as support its ongoing clinical trials.
What is the lead product candidate of Krystal Biotech?
The lead product candidate of Krystal Biotech is KB103, an investigational gene therapy designed for the treatment of dystrophic epidermolysis bullosa. It has shown promising results in clinical trials and highlights the company's innovative approach to gene therapy.
What is the main focus of Krystal Biotech's research?
Krystal Biotech primarily focuses on developing treatments for skin-related genetic diseases. Their lead product candidates aim to address conditions such as dystrophic epidermolysis bullosa, which is characterized by fragile skin and blister formation.
What is the significance of dystrophic epidermolysis bullosa?
Dystrophic epidermolysis bullosa (DEB) is a rare genetic disorder that results in extremely fragile skin. It significantly impacts patients' quality of life, necessitating innovative therapies such as those developed by Krystal Biotech.
What is the target market for Krystal Biotech's products?
The primary target market for Krystal Biotech's products includes patients with rare genetic disorders, particularly those affecting the skin. These conditions often have limited treatment options, highlighting the need for innovative therapies.
What is the technology platform used by Krystal Biotech?
Krystal Biotech utilizes its proprietary SkinTE technology, which involves delivering genetic material directly to the skin cells to promote healing and repair for various dermatological conditions.
When was Krystal Biotech founded?
Krystal Biotech was founded in 2016 and has since grown into a leader in gene therapy, aiming to transform the treatment landscape for patients suffering from various genetic disorders.
Where is Krystal Biotech located?
Krystal Biotech is headquartered in Pittsburgh, Pennsylvania. The company's location supports its commitment to innovation in biotechnology and helps foster collaboration with local academic and research institutions.
Who are the key executives at Krystal Biotech?
Key executives at Krystal Biotech include Chairman and CEO Krish S. Krishnan and CMO F. Fen Zhang. Their collective experience in the pharmaceutical and biotech industries drives the company's strategic vision and growth.
What is the current price of Krystal Biotech, Inc. - Common Stock?
The current price of Krystal Biotech, Inc. - Common Stock is 132.18
When was Krystal Biotech, Inc. - Common Stock last traded?
The last trade of Krystal Biotech, Inc. - Common Stock was at 4:00 pm EDT on May 9th, 2025
What is the market capitalization of Krystal Biotech, Inc. - Common Stock?
The market capitalization of Krystal Biotech, Inc. - Common Stock is 2.94B
How many shares of Krystal Biotech, Inc. - Common Stock are outstanding?
Krystal Biotech, Inc. - Common Stock has 22.21M shares outstanding.